Plasma-based Biomarkers for Early Detection of Pancreatic Cancer Plasma-based Biomarkers for Early Detection of Pancreatic Cancer Biomarkers for early detection of pancreatic ductal adenocarcinoma, also known as pancreatic cancer (PC), are desperately needed because most patients present with late stage disease when 5 year survival is ~20%. Plasma is an ideal source for biomarkers because blood circulates through every organ. Because biologically informative molecules are obscured by large, highly abundant proteins in plasma (albumin, transferrin, immunoglobulin, etc.), we subjected plasma to 3kDa ultrafiltration followed by mass spectrometry. In an effort to identify PC biomarkers we employed HPLC-tandem mass spectrometry (LC-MS/MS) to identify peptides in the low molecular weight (LMW) fraction of plasma from patients with PC that could not be identified by analyzing whole plasma. We found peptides derived from two proteins (QSOX1 and SerpinF2) shared among 19 of 20 PC patients, but never found peptides corresponding to these proteins in plasma from 42 normal donors. QSOX1 has not been wellstudied, but has been suggested to have anti-apoptotic activity in tumors. SerpinF2 has been implicated in tumor cell invasion leading to metastasis. The first goal of this pilot study is to determine if these proteins are specific for PC by analyzing plasma from patients with benign pancreaticobiliary conditions as well as cholangiocarcinoma. These patients are ideal controls because it can be very difficult to clinically differentiate PC from other pancreatic or biliary diseases. Because antibodies are available for QSOX1 and SerpinF2, our second goal is to perform immunohistochemistry on confirmed, historical cases of pancreatic ductal adenocarcinoma to determine if tumor, stroma, or inflammatory infiltrate is expressing either QSOX1 or SerpinF2.
|Effective start/end date||1/1/09 → 12/31/09|
- Mayo Clinic Arizona: $20,000.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.